Polycyclic Sulfones for Blood-Brain Barrier Neuroprotection

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapeutic solutions for neurological disorders, particularly those targeting the central nervous system, are hindered by the poor pharmacokinetic properties of glial cell line-derived neurotrophic factor (GDNF), which does not cross the blood-brain barrier and requires invasive delivery methods, limiting their clinical efficacy.

Innovation Solution

Development of novel polycyclic sulfones that exhibit potent GFRα1-RET activity, mimicking GDNF biological effects and potentially overcoming the limitations of GDNF by enhancing tissue penetration and efficacy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If GDNF is used as a therapeutic agent for neurological disorders, then neuroprotective effects are achieved, but the compound cannot cross the blood-brain barrier and requires invasive delivery

Engineering Contradiction:

Improveneuroprotective efficacyVSAvoiddelivery method

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent creates small-molecule compounds that copy and mimic the biological activity of GDNF by targeting the same GFRα1-RET receptor complex. These molecular copies replicate the neuroprotective effects of GDNF without requiring its complex protein structure, enabling them to cross the blood-brain barrier and be delivered through simple oral administration rather than invasive stereotaxic surgery.

Inventive Principle:

Principle #26Copying

2Reliability

If GDNF is used for treating neurological disorders, then neurotrophic effects are achieved, but the treatment requires invasive intracranial delivery via stereotaxic surgery

Engineering Contradiction:

Improveneurotrophic activityVSAvoiddelivery system

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The invention develops simplified molecular copies of GDNF's action mechanism. Instead of delivering the complex GDNF protein that requires sophisticated delivery systems, the patent uses small-molecule sulfones that replicate GDNF's ability to activate the GFRα1-RET signaling pathway, thereby achieving neurotrophic effects through much simpler oral delivery methods.

Inventive Principle:

Principle #26Copying

3Adaptability or versatility

If GDNF is administered systemically, then broad neuroprotective coverage is achieved, but the compound fails to penetrate the blood-brain barrier

Engineering Contradiction:

Improvetissue penetrationVSAvoidblood-brain barrier penetration

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent fundamentally changes the physical and chemical parameters of the therapeutic agent from a large protein (GDNF) to small-molecule sulfones with molecular weights suitable for blood-brain barrier penetration. This parameter change allows the compounds to cross the blood-brain barrier via passive diffusion while maintaining the ability to activate neuronal survival pathways through GFRα1-RET receptor binding.

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS20260042770A1Novel sulfones and their use as neuroprotective and/or neurorestorative agents

Publication Date: 2026.02.12 GENECODE AS

AI summary

A compound of general formula (I)or a pharmaceutically acceptable salt and/or solvate thereof, and the process for manufacturing the compound of general formula (I). Also, a pharmaceutical composition that includes a compound of general formula (I), and the use of compounds of general formula (I) as neuroprotective and/or neurorestorative agents, in particular for use in the treatment of neurological disorders.